Back to Search
Start Over
Emergency myelopoiesis contributes to immune cell exhaustion and pulmonary vascular remodelling
- Source :
- Br J Pharmacol
- Publication Year :
- 2020
- Publisher :
- Wiley, 2020.
-
Abstract
- Background and purpose Pulmonary hypertension (PH) secondary to chronic lung disease (World Health Organization Group 3 PH) is deadly, with lung transplant being the only available long-term treatment option. Myeloid-derived cells are known to affect progression of both pulmonary fibrosis and PH, although the mechanism of action is unknown. Therefore, we investigated the effect of myeloid cell proliferation induced by emergency myelopoiesis on development of PH and therapy directed against programmed death-ligand 1 (PD-L1), expressed by myeloid cells in prevention of pulmonary vascular remodelling. Experimental approach LysM.Cre-DTR ("mDTR") mice were injected with bleomycin (0.018 U·g-1 , i.p.) while receiving either vehicle or diphtheria toxin (DT; 100 ng, i.p.) to induce severe PH. Approximately 4 weeks after initiation of bleomycin protocol, right ventricular pressure measurements were performed and tissue samples collected for histologic assessment. In a separate experiment, DT-treated mice were given anti-PD-L1 antibody (αPD-L1; 500 μg, i.p.) preventive treatment before bleomycin administration. Key results Mice undergoing induction of emergency myelopoiesis displayed more severe PH, right ventricular remodelling and pulmonary vascular muscularization compared to controls, without a change in lung fibrosis. This worsening of PH was associated with increased pulmonary myeloid-derived suppressor cell (MDSC), particularly polymorphonuclear MDSC (PMN-MDSC). Treatment with αPD-L1 normalized pulmonary pressures. PD-L1 expression was likewise found to be elevated on circulating PMN-MDSC from patients with interstitial lung disease and PH. Conclusions and implications PD-L1 is a viable therapeutic target in PH, acting through a signalling axis involving MDSC. Linked articles This article is part of a themed issue on Risk factors, comorbidities, and comedications in cardioprotection. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v178.1/issuetoc.
- Subjects :
- 0301 basic medicine
medicine.medical_specialty
Myeloid
Pulmonary Fibrosis
Vascular Remodeling
Bleomycin
Gastroenterology
Article
Vascular remodelling in the embryo
Mice
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Internal medicine
Pulmonary fibrosis
Animals
Humans
Medicine
Myelopoiesis
Pharmacology
Lung
business.industry
Myeloid-Derived Suppressor Cells
Interstitial lung disease
medicine.disease
Pulmonary hypertension
030104 developmental biology
medicine.anatomical_structure
chemistry
business
030217 neurology & neurosurgery
Subjects
Details
- ISSN :
- 14765381 and 00071188
- Volume :
- 178
- Database :
- OpenAIRE
- Journal :
- British Journal of Pharmacology
- Accession number :
- edsair.doi.dedup.....8cb9de6c674788c6029d48d7204ae296
- Full Text :
- https://doi.org/10.1111/bph.14945